The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Research output: Contribution to journal › Editorial › peer-review

Access to Document

@article{eba368ef3d3f4c2e9e080cebeda1f967,

title = "The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?",

author = "Tatham, \{Kate C.\} and Manu Shankar-Hari and Arabi, \{Yaseen M.\}",

year = "2021",

month = oct,

day = "7",

doi = "10.1007/s00134-021-06540-w",

language = "Undefined/Unknown",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer",

}